Corpus Resources Plc (COR) — Research Note

Executive summary

Corpus Resources Plc is a UK Main Market-listed cash shell (formerly Curzon Energy Plc) that has had no operating revenue across the five-year period covered, having written off its only historic asset — the Coos Bay coal-bed methane project in Oregon — and spent the period since 2020 attempting (and failing) to execute a reverse takeover into either plastics recycling (Poseidon), critical metals (TM2/SSSIG) or oil & gas. The operating trajectory is one of progressive value destruction, a 2024 Company Voluntary Arrangement that wiped out ~£3.3m of legacy creditor and loan liabilities in exchange for ~92% dilution, multiple sub-penny placings, and most recently a temporary listing suspension on 1 May 2026 because the 2025 audited accounts are late 2026-05-01 RNS. The single most important point for valuation is that the equity has no underlying business — it is a listed-shell option whose value depends entirely on management successfully introducing an external asset before working capital runs out again.

Fair value estimate

Methodology: Cash-shell NAV plus listing-premium optionality. There is no operating business to value via DCF, multiples, or sum-of-parts.

Inputs from the filings:

• April 2026 placing: £311,000 raised at £0.0001 per share, lifting share count to 6,336,306,795 2026-04-23 RNS.
• Latest published equity: £8,102 of net assets at 30 June 2025; current liabilities of £350,864; cash £68,212 2025-09-22 H1 2025.
• Post the April 2026 raise, indicative net assets are roughly £300–350k (cash + receivables less accruals), or ~0.005p per share on a pure NAV basis.
• UK Main Market cash shells typically trade at a multiple of NAV reflecting the listing's optionality value — but Corpus's listing is currently suspended 2026-05-01 RNS, which materially impairs that premium until the audit is delivered.

Fair value range: 0.005p – 0.02p per share, implying a market cap of £0.3m – £1.3m. The low end is liquidation-style NAV; the high end assumes the listing is restored and a credible RTO target emerges (the April 2026 director subscriptions at 0.01p suggest insiders themselves see fair value broadly in this zone).

Mid-point implied market cap: ~£0.8m. Versus the latest disclosed market cap of £1.0m, this implies modest downside of ~–20%, with a wide range. The current 1.0m valuation already prices in some optimism about the suspension being lifted and an RTO closing.

Sector context

The ICB classification is Energy, but this is a misclassification of substance: there are no producing or developing energy assets. Operationally Corpus is a shell-company / cash-shell vehicle. Comparable UK-listed shells (Main Market, equity-shares-transition category) include names such as Aterian plc, Cabouchon plc and various other sub-£5m RTO vehicles. Against these peers Corpus's profile is below average — it has been in shell mode for longer, has burned through multiple RTO attempts, and is currently suspended, all of which makes it lower-quality than a freshly-recapitalised shell.

Investment thesis

1. Recapitalised, debt-free balance sheet post-CVA. The February 2025 completion of the CVA wiped out ~US$2.6m of borrowings and ~US$1.3m of admin creditors, leaving the entity effectively debt-free and with a clean structure for an incoming RTO target 2025-09-22 H1 2025, Note 7. A clean UK Main Market listing has scarcity value to private companies wanting a quick London quote.
2. Active management and new technical director. The April 2026 appointment of James Stenhouse, an oil-services operator who personally subscribed £106,000, plus the chairman's £55k subscription, suggests insiders are aligned and that there are specific opportunities under evaluation, including an "existing non-operated gas production facility" and a "near-term oil field" 2026-04-23 RNS; 2025-09-22 H1 2025.
3. Low cost base extends optionality. Reported H1 2025 administrative expenses of US$124k (versus US$402k in H1 2024) demonstrate a sharply reduced run-rate, meaning the £311k April 2026 raise theoretically buys multiple quarters of optionality to find a target 2025-09-22 H1 2025, Note 5.

Key risks

1. Listing suspended and audit overdue. Trading has been suspended since 1 May 2026 pending publication of 2025 audited accounts, expected by end June 2026. A further delay or qualified opinion would severely damage the shell's value 2026-05-01 RNS; 2026-04-21 RNS.
2. Track record of failed RTOs. SSSIG/LCMM (terminated Feb 2021), Poseidon Plastics (terminated April 2023), and TM2 (exclusivity lapsed) all collapsed despite extended periods of due diligence and director-funded extensions 2024-08-19 GM notice; 2022-04-29 Final Results. There is no operational pattern of completing deals.
3. Permanent dilution from continuous sub-penny placings. Share count grew from 99.6m (mid-2024) to 6.34bn (April 2026) — a >60× increase — at successively lower prices, including the April 2026 round at £0.0001. Any future RTO will likely require further substantial dilution at depressed prices 2025-09-22 H1 2025, Note 4; 2026-04-23 RNS.

Operating leverage

There is no operating leverage to discuss because there is no operating business. The cost base is almost entirely fixed corporate overhead — directors' fees, audit, regulatory compliance, broker fees — running at roughly £100–250k per annum 2025-09-22 H1 2025, Note 5. Incremental revenue is zero on zero. The investor's stated requirement that "an upside revenue surprise turn into a multiple of profit" cannot be evaluated because there is no revenue line. Any operating leverage would only emerge inside a future RTO target whose identity, sector, and cost structure are currently unknown.

Value-trap signals

• Repeated dilutive placings at successively lower prices (0.0003 → 0.00015 → 0.0001 per share).
• Multiple failed RTO attempts over five years.
• Currently suspended listing and overdue audited accounts.
• Going-concern emphasis-of-matter present in every set of accounts reviewed.
• Director compensation accrued but unpaid for multiple years prior to CVA — a sign of structural cash starvation.
• Related-party loan history (chairman previously also Executive Chairman of Poseidon Plastics, the RTO counterparty) 2022-04-29 Final Results.

Earnings vs. expectations

The company does not give earnings guidance and is not covered by sell-side analysts, so there is no formal beat/miss record. However, management commitments on deal timing have repeatedly slipped: the Poseidon RTO was promised "in the near term" across 2021, 2022 and 2023 announcements before being abandoned; the post-CVA strategy of targeting acquisitions has now been ongoing for over 18 months without completion 2022-04-29; 2023-09-28; 2025-09-22. The most quantifiable "result" is the H1 2025 reported profit of US$3.7m — driven entirely by non-recurring CVA write-backs of US$3.99m — which is a one-off accounting entry, not operational performance 2025-09-22 H1 2025.

Conviction

Conviction: 2 (low). I'm confident the stock is not a fit for this strategy and that there is no operating business to anchor a fundamental fair value, but the residual value depends on (a) whether the audit is delivered and the suspension is lifted, and (b) whether an RTO target lands at all — both of which are binary and unknowable from the filings. Anchors: the cash-shell character is unambiguous, the listing suspension is documented, and the dilution history is precise. Limits: the entire equity story is option value on an unknown future asset; the latest audited accounts are not yet available; suspension/RTO outcomes are binary.

Driver scoring (0-100)

ai_beneficiary: 2 — Zero exposure. Energy/shell vehicle with no AI angle whatsoever; this is the antithesis of an AI-receiver name. operating_leverage: 5 — No operations means no leverage to incremental revenue. Fixed shell overheads but no top line to leverage them with. earnings_surprise_trend: 25 — No analyst consensus to beat, but management's repeated failure to deliver promised RTOs scores at the lower end. Not a "50/not enough data" — there's a clear pattern of misses on stated transaction timelines. cyclicality: 40 — Hard to classify a shell; if it remains/becomes E&P focused as currently signalled, that would be moderately cyclical, but at present it has no cycle exposure. moat: 5 — A UK Main Market listing has some scarcity value to private targets, but no economic moat. leverage: 15 — Post-CVA balance sheet is essentially debt-free with ~£300k of net assets. Clean on this dimension, though "low debt with no EBITDA" is not the same as a fortress. earnings_quality: 15 — Reported H1 2025 profit was a non-cash CVA write-back. Repeated restatements of recent prior-year creditors, history of waived/deferred director compensation, related-party RTO counterparties. management_quality: 20 — Repeated failed deals, sub-penny dilution, related-party financing arrangements, and missed reporting deadline. New board (Glass/Stenhouse) has yet to demonstrate execution. growth_momentum: 5 — Zero revenue throughout the period; no momentum to assess.

Overall score

overall_score: 25 / 1000.

This fits none of the investor's three explicit preferences: no AI-receiver exposure, no operating leverage (no operations), no downside protection (suspended listing, going-concern qualified, repeated dilution), and the valuation discipline test is moot because the asset being valued is option-value on an unknown future RTO. Even acknowledging the post-CVA clean balance sheet and director alignment, this is squarely in the "poor fit, structurally challenged" band.